Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Byung Ju Jung, Joo Young Kim, Jae Hyung Lee, Jiwon Baek, Kook Lee, Won Ki Lee, Byung Ju Jung, Joo Young Kim, Jae Hyung Lee, Jiwon Baek, Kook Lee, Won Ki Lee
Abstract
This retrospective study was to compare the efficacy of intravitreal injection of ranibizumab and aflibercept for patients with pachychoroid neovasculopathy. 54 eyes were initially treated with 3 monthly loading injections of ranibizumab or aflibercept. Treatment switching from ranibizumab to aflibercept, and aflibercept to photodynamic therapy was done at 3 months in case of incomplete fluid absorption. At 3 months, the rate of complete fluid absorption was significantly higher in the aflibercept-treated group than in the ranibizumab-treated group (82.6% vs 51.6%, p = 0.018). The mean reduction of subfoveal choroidal thickness was significantly greater in the aflibercept group than in the ranibizumab group (-35 µm vs -9 µm, p = 0.013). There was no significant difference between the two groups in terms of visual improvement or decrease in central macular thickness. Complete fluid absorption was achieved after switching from ranibizumab to aflibercept in 13 of 15 eyes (86.7%). Adjunctive photodynamic therapy was required in 6 eyes. In conclusion, treatment mainly with anti-vascular endothelial growth factor effectively improved visual acuity within 12 months (from 20/56 to 20/44 at 3 months and to 20/36 at 12 months). Aflibercept was superior to ranibizumab in achieving dry macula and reducing choroidal thickness at 3 months.
Conflict of interest statement
The authors declare no competing interests.
Figures
References
- Warrow DJ, Hoang QV, Freund KB. Pachychoroid Pigment Epitheliopathy. Retina-J Ret Vit Dis. 2013;33:1659–1672. doi: 10.1097/IAE.0b013e3182953df4.
- Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina. 2015;35:1–9. doi: 10.1097/IAE.0000000000000331.
- Balaratnasingam C, et al. Polypoidal Choroidal Vasculopathy: A Distinct Disease or Manifestation of Many? Retina. 2016;36:1–8. doi: 10.1097/IAE.0000000000000774.
- Miyake M, et al. Pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep. 2015;5:16204. doi: 10.1038/srep16204.
- Hata M, et al. Intraocular Vascular Endothelial Growth Factor Levels in Pachychoroid Neovasculopathy and Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2017;58:292–298. doi: 10.1167/iovs.16-20967.
- Matsumoto H, et al. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration. Jpn J Ophthalmol. 2018;62:144–150. doi: 10.1007/s10384-018-0562-0.
- Cheung CMG, et al. Polypoidal Choroidal Vasculopathy: Definition, Pathogenesis, Diagnosis, and Management. Ophthalmology. 2018;125:708–724. doi: 10.1016/j.ophtha.2017.11.019.
- Johnston RL, et al. UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV: Incidence of Blindness and Sight Impairment in Ranibizumab-Treated Patients. Ophthalmology. 2016;123:2386–2392. doi: 10.1016/j.ophtha.2016.07.037.
- Heier JS, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–2548. doi: 10.1016/j.ophtha.2012.09.006.
- Yang J, et al. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. Mol Pharm. 2014;11:3421–3430. doi: 10.1021/mp500160v.
- Padron-Perez N, et al. Changes in Choroidal Thickness After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor in Pachychoroid Neovasculopathy. Invest Ophthalmol Vis Sci. 2018;59:1119–1124. doi: 10.1167/iovs.17-22144.
- Mantel, I., Gillies, M. C. & Souied, E. H. Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration. Surv Ophthalmol, 10.1016/j.survophthal.2018.02.004 (2018).
- Wong, T. Y. et al. Efficacy and Safety of Intravitreal Aflibercept and Ranibizumab in Asian Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses From the View Trials. Retina, 10.1097/IAE.0000000000001986 (2017).
- Yanagi Y, et al. Prevalence and Risk Factors for Nonexudative Neovascularization in Fellow Eyes of Patients With Unilateral Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Invest Ophthalmol Vis Sci. 2017;58:3488–3495. doi: 10.1167/iovs.16-21167.
- Hata M, et al. Efficacy of intravitreal injection of aflibercept in neovascular age-related macular degeneration with or without choroidal vascular hyperpermeability. Invest Ophthalmol Vis Sci. 2014;55:7874–7880. doi: 10.1167/iovs.14-14610.
- Koizumi H, et al. Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159:627–633. doi: 10.1016/j.ajo.2014.12.025.
- Dansingani KK, Balaratnasingam C, Naysan J, Freund KB. En Face Imaging of Pachychoroid Spectrum Disorders with Swept-Source Optical Coherence Tomography. Retina. 2016;36:499–516. doi: 10.1097/IAE.0000000000000742.
- Lee WK, Baek J, Dansingani KK, Lee JH, Freund KB. Choroidal Morphology in Eyes with Polypoidal Choroidal Vasculopathy and Normal or Subnormal Subfoveal Choroidal Thickness. Retina. 2016;36(1):S73–S82. doi: 10.1097/IAE.0000000000001346.
- Kitaya N, et al. Features of abnormal choroidal circulation in central serous chorioretinopathy. Br J Ophthalmol. 2003;87:709–712. doi: 10.1136/bjo.87.6.709.
- Lee JH, Lee WK. One-Year Results of Adjunctive Photodynamic Therapy for Type 1 Neovascularization Associated with Thickened Choroid. Retina. 2016;36:889–895. doi: 10.1097/IAE.0000000000000809.
- Gomi F, et al. Initial Versus Delayed Photodynamic Therapy in Combination with Ranibizumab for Treatment of Polypoidal Choroidal Vasculopathy: The Fujisan Study. Retina. 2015;35:1569–1576. doi: 10.1097/IAE.0000000000000526.
- Lee WK, et al. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial. JAMA Ophthalmol. 2018;136:786–793. doi: 10.1001/jamaophthalmol.2018.1804.
- Age-Related Eye Disease Study Research, G The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study Report Number 6. Am J Ophthalmol. 2001;132:668–681. doi: 10.1016/S0002-9394(01)01218-1.
- Sho K, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol. 2003;121:1392–1396. doi: 10.1001/archopht.121.10.1392.
- Sonoda S, et al. Choroidal structure in normal eyes and after photodynamic therapy determined by binarization of optical coherence tomographic images. Invest Ophthalmol Vis Sci. 2014;55:3893–3899. doi: 10.1167/iovs.14-14447.
- Ting DSW, et al. Choroidal Remodeling in Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A 12-month Prospective Study. Sci Rep. 2017;7:7868. doi: 10.1038/s41598-017-08276-4.
Source: PubMed